The independent members of the Board of Directors of Soleno approved the grant of a non-qualified stock option to purchase 70,000 shares of common stock to each of
The options have an exercise price of
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.
Source: Soleno Therapeutics